WO2009026128A3 - Gene expression markers of recurrence risk in cancer patients after chemotherapy - Google Patents

Gene expression markers of recurrence risk in cancer patients after chemotherapy Download PDF

Info

Publication number
WO2009026128A3
WO2009026128A3 PCT/US2008/073261 US2008073261W WO2009026128A3 WO 2009026128 A3 WO2009026128 A3 WO 2009026128A3 US 2008073261 W US2008073261 W US 2008073261W WO 2009026128 A3 WO2009026128 A3 WO 2009026128A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapy
gene expression
cancer patients
expression markers
recurrence risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/073261
Other languages
French (fr)
Other versions
WO2009026128A2 (en
Inventor
Steven Shak
Joffre Baker
Carl Yoshizawa
Joseph Sparano
Robert Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Aventis Inc
Original Assignee
Genomic Health Inc
Aventis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Aventis Inc filed Critical Genomic Health Inc
Priority to EP08797949A priority Critical patent/EP2191020A2/en
Priority to AU2008289148A priority patent/AU2008289148A1/en
Priority to CA2694703A priority patent/CA2694703A1/en
Publication of WO2009026128A2 publication Critical patent/WO2009026128A2/en
Publication of WO2009026128A3 publication Critical patent/WO2009026128A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to genes, the expression levels of which are correlated with likelihood of breast cancer recurrence in patients after tumor resection and chemotherapy.
PCT/US2008/073261 2007-08-16 2008-08-15 Gene expression markers of recurrence risk in cancer patients after chemotherapy Ceased WO2009026128A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08797949A EP2191020A2 (en) 2007-08-16 2008-08-15 Gene expression markers of recurrence risk in cancer patients after chemotherapy
AU2008289148A AU2008289148A1 (en) 2007-08-16 2008-08-15 Gene expression markers of recurrence risk in cancer patients after chemotherapy
CA2694703A CA2694703A1 (en) 2007-08-16 2008-08-15 Gene expression markers of recurrence risk in cancer patients after chemotherapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US95638007P 2007-08-16 2007-08-16
US60/956,380 2007-08-16
US97018807P 2007-09-05 2007-09-05
US60/970,188 2007-09-05
US97049007P 2007-09-06 2007-09-06
US60/970,490 2007-09-06

Publications (2)

Publication Number Publication Date
WO2009026128A2 WO2009026128A2 (en) 2009-02-26
WO2009026128A3 true WO2009026128A3 (en) 2009-09-11

Family

ID=39871878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/073261 Ceased WO2009026128A2 (en) 2007-08-16 2008-08-15 Gene expression markers of recurrence risk in cancer patients after chemotherapy

Country Status (5)

Country Link
US (2) US20090125247A1 (en)
EP (2) EP2228457A1 (en)
AU (1) AU2008289148A1 (en)
CA (1) CA2694703A1 (en)
WO (1) WO2009026128A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2258872T3 (en) * 2002-03-13 2013-11-18 Genomic Health Inc Gene expression profiling in tumor tissue biopsies
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ES2482692T3 (en) * 2008-05-12 2014-08-04 Genomic Health, Inc. Tests to predict the receptivity of cancer patients to chemotherapy treatment options
WO2010118782A1 (en) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
US20110217297A1 (en) * 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US20110246677A1 (en) * 2010-04-05 2011-10-06 Lsi Logic Corporation Systems and methods for controlling commands for target devices
GB201012590D0 (en) * 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
US20120052079A1 (en) * 2010-08-10 2012-03-01 Dana-Farber Cancer Institute, Inc. Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
WO2012167145A2 (en) * 2011-06-01 2012-12-06 University Of Southern California Genome-scale analysis of aberrant dna methylation in colorectal cancer
CA2869313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Gene expression panel for breast cancer prognosis
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2016025717A1 (en) 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
EP3455761B1 (en) 2016-05-10 2021-12-22 Mayo Foundation for Medical Education and Research Methods and materials for staging and treating skin cancer
US12473599B2 (en) 2018-07-25 2025-11-18 Skylinedx B.V. Gene signatures for predicting metastasis of melanoma and patient prognosis
CN114959026A (en) * 2022-04-15 2022-08-30 深圳市陆为生物技术有限公司 Application of a reagent for detecting genes in the preparation of a product for evaluating the recurrence risk of breast cancer patients

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070798A2 (en) * 2000-03-16 2001-09-27 K.U. Leuven Research & Development Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006052862A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2007039128A1 (en) * 2005-09-21 2007-04-12 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DK2258872T3 (en) * 2002-03-13 2013-11-18 Genomic Health Inc Gene expression profiling in tumor tissue biopsies
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP3170906B1 (en) * 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
CA2585561C (en) * 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
US20100191691A1 (en) * 2009-01-23 2010-07-29 Hudson Jr James Thomas Method for computer-aided decision-making system and method that utilizes product, services and/or venue values and personality value matching, incorporating groups and outside values

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070798A2 (en) * 2000-03-16 2001-09-27 K.U. Leuven Research & Development Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006052862A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2007039128A1 (en) * 2005-09-21 2007-04-12 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERTUCCI F ET AL: "Gene Expression Profiles of Poor-Prognosis Primary Breast Cancer Correlate with Survival", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 11, no. 8, 15 April 2002 (2002-04-15), pages 863 - 872, XP001146244, ISSN: 0964-6906 *
BERTUCCI F ET AL: "Prognosis of Breast Cancer and Gene Expression Profiling Using Dna Arrays", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 975, 1 December 2002 (2002-12-01), pages 217 - 231, XP001146250, ISSN: 0077-8923 *
PAIK S ET AL: "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 351, no. 27, 30 December 2004 (2004-12-30), pages 2817 - 2826, XP008043033, ISSN: 1533-4406 *
PAWITAN YUDI ET AL: "Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 6, 3 October 2005 (2005-10-03), pages R953 - R964, XP021011896, ISSN: 1465-5411 *
SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424 *
TANNER M ET AL: "Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 24, no. 16, 1 June 2006 (2006-06-01), pages 2428 - 2436, XP002444117, ISSN: 0732-183X *
THORAT ET AL: "Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors?", CURRENT DIAGNOSTIC PATHOLOGY, CHURCHILL LIVINGSTONE, vol. 13, no. 2, 4 April 2007 (2007-04-04), pages 116 - 125, XP022019328, ISSN: 0968-6053 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
EP2191020A2 (en) 2010-06-02
EP2228457A1 (en) 2010-09-15
CA2694703A1 (en) 2009-02-26
AU2008289148A1 (en) 2009-02-26
US20090125247A1 (en) 2009-05-14
WO2009026128A2 (en) 2009-02-26
US20110171641A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2011094483A3 (en) Immune gene signatures in cancer
WO2009053041A3 (en) Identification of tumor-associated markers for diagnosis and therapy
EP2592156A3 (en) Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
WO2010141738A3 (en) Compositions and method for inhibiting tumor growth
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2010059702A3 (en) Recurrent gene fusions in prostate cancer
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
IL201217A0 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007134210A8 (en) Methods and compositions for the diagnosis and treatment of cancer
WO2013093508A3 (en) Wnt pathway inhibitors
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2009009432A3 (en) Recurrent gene fusions in prostate cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2012135592A3 (en) Theranostic imaging agents and methods of use
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2011122857A3 (en) Composition for predicting prognosis of breast cancer, and kit containing same
WO2009153660A3 (en) Gene expression signatures for lung cancers
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2007100859A3 (en) Gene predictors of response to metastatic colorectal chemotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08797949

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2694703

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 582939

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008289148

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008289148

Country of ref document: AU

Date of ref document: 20080815

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008797949

Country of ref document: EP